Developing an instrument to analyze proteins at scale, pre-revenue.
$2.06close as of 2026-10-16
+92.5% over 1Y · 75.7 points ahead of the S&P 500
NAUTS&P 500 (SPY), rebased to NAUT's first close
“Can Tau and AKT1 assays establish demand for Voyager while the Broadscale Assay launch remains without a timeline?”
Editorial note · updated 2026-10-08
The TenQ Radar
Nautilus Biotechnology in 36 checks
Nautilus Biotechnology on the TenQ Radar: value, growth, quality, health, shareholder returns and trend. The fuller the shape, the stronger the company. Behind each axis are six pass-or-fail checks from its filings, spelled out in the chapters below. Point at an axis to see them.
The business itself is the question here: 10 of 36 checks passed.
The Nautilus Biotechnology story
What drives Nautilus Biotechnology, what its price assumes and what could change the story, written from its own filings.
First revenue arrives. Nautilus recognized $0.2 million of revenue in the quarter to June 2026, primarily from a Michael J. Fox Foundation grant, alongside its first Early Access Program service revenue.
A narrower launch path. Nautilus is reallocating resources toward proteoform assays, which measure functional protein variants, after broadscale testing failed to support general availability in 2027.
Commercialization remains costly. Operating expenses declined 7% to $15.9 million in the quarter to June 2026, but Nautilus still reported a net loss of $14.5 million.
Q2 '26 · quarter to 30 June 2026 · reported 28 July 2026 · Earnings release ↗
Revenue$190,000+$190,000vs 2025
Earnings-$14M+$564,000vs 2025+$228,000vs Q1
What the release says
Highlights
Nautilus Biotechnology recognized its first revenue in Q2 2026, including grant revenue from the Michael J. Fox Foundation and service revenue from its first Iterative Mapping Early Access Program customer.
The company expanded its commercial organization to three team members, including a new VP of Global Sales, to drive engagement ahead of the Voyager Platform commercial launch.
Nautilus has selected AKT1 as its first oncology proteoform, with Early Access availability expected in late 2026, and is accelerating its proteoform applications roadmap by reallocating resources from broadscale assay development.
Operating expenses decreased by 7% year-over-year to $15.9 million, and cash, cash equivalents, and investments totaled $129.2 million as of June 30, 2026.
What management expects
The company expects to launch the Voyager Platform for pre-orders in early 2027, with instrument shipments beginning in mid 2027, alongside general availability of Tau and AKT1 Proteoforms Assay consumable kits.
General availability of a second oncology proteoforms assay and expanded proteoform portfolio capabilities is anticipated in mid 2027, with further portfolio expansion in late 2027.
Nautilus plans to report back on a commercial timeline for the Broadscale Assay at a future date, as development work continues to address key improvement areas.
Key risks
New Development challenges have caused, and may continue to cause, delays or inhibit the ability to commercialize platform assays in one or more application areas, and if the company cannot supplement its initial platform release with subsequent consumable releases or achieve expanded capabilities, it may lose customers or be limited in market adoption.
New The company is reallocating resources from broadscale assay development to accelerate proteoform application development due to the need for further improvements to the broadscale assay and increased market demand for proteoforms, which could impact the timing and scope of future product offerings.
Nautilus is a development stage company that has incurred net losses in every period to date, has not yet commercialized any products, and may never achieve profitability, which could impact its ability to continue operations.
The business is entirely dependent on the successful development and commercialization of the Nautilus Voyager platform, which remains in the development stage and could face delays, technical challenges, or market acceptance issues.
Nautilus relies on third parties for certain aspects of development and commercialization, and any failure by these partners to deliver on time or to specifications could negatively impact timelines, costs, or product performance.
The company is dependent on single source suppliers for some components and materials used in the Nautilus Voyager platform, and the loss of any of these suppliers could disrupt development or commercial supply and harm the business.
AI summary of the company's filings, every number checked against them · 8 October 2026 · Sources: earnings release, 10-K, 10-Q
Earnings alerts
An email when Nautilus Biotechnology reports, with its results and highlights. Free with a watchlist account.
I
Value
●●●●●●0/6
Expensive against its own history and its sector (judged on sales, as it is not yet profitable): the price asks a lot of the business.
-no history
-no history
-19.8%cash earned per $ of price
-whole-business multiple
What does “Value” actually mean?
Value asks what you pay for each dollar of earnings, sales or cash the business produces. A high multiple isn't automatically bad - fast growers earn theirs - but a price far above the company's own history means the market expects a lot to go right. We compare each multiple to the company's own past and to its sector, never to a universal rule.
not profitable: no free cash flow or earnings for the price to rest on
II
Growth
●●●●●●0/6
Growth is weak or inconsistent. The trend, not the story, is the problem.
-vs the year before
-compound annual
-net income growth
-compound annual
Revenue history
Is NAUT's revenue growing?
Not enough history to chart.
Period
Revenue ($)
Q2 2025
0
Q2 2026
190,000
→No revenue history has been filed for NAUT yet.
What this measures
The money customers paid, before any costs are taken out. Each bar is one quarter or, on the annual view, a full financial year; the last annual bar may be the trailing twelve months, which the footnote marks.
What good looks like. Growth that repeats, rather than one strong year carrying the chart, and a trailing twelve months keeping pace with the last full year.
If it rises or falls. Revenue is the hardest line to flatter, so a rise is the most trustworthy kind of growth. A fall puts pressure on every margin below it, because costs rarely come down as quickly as sales do.
Revenue by productInsight
Where does Nautilus Biotechnology's revenue come from?
→Grant Revenue is Nautilus Biotechnology's larger product line at $180,000, 95% of $190,000 in 2026Q2, against $10,000 for Service Revenue.
Source: SEC filings - segment disclosures (XBRL notes) · as at 2026-06-30
Profit history
Is NAUT's net profit growing?
◌ dashed quarter = Q4 derived from the annual filing minus Q1, Q2 and Q3 (the SEC never receives a Q4 report)
Period
Net income ($)
Q2 2020
-3.4M
Q3 2020
-4.0M
Q1 2021
-8.4M
Q2 2021
-10.7M
Q3 2021
-14.5M
Q4 2021
-16.7M
Q1 2022
-15.8M
Q2 2022
-14.7M
Q3 2022
-14.1M
Q4 2022
-13.4M
Q1 2023
-15.0M
Q2 2023
-15.8M
Q3 2023
-15.9M
Q4 2023
-17.0M
Q1 2024
-18.7M
Q2 2024
-18.0M
Q3 2024
-16.4M
Q4 2024
-17.6M
Q1 2025
-16.6M
Q2 2025
-15.0M
Q3 2025
-13.6M
Q4 2025
-13.8M
Q1 2026
-14.7M
Q2 2026
-14.5M
2020
-15.6M
2021
-50.3M
2022
-57.9M
2023
-63.7M
2024
-70.8M
2025
-59.0M
→The company lost $59M in 2025, less than the $71M it lost the year before. The losses are narrowing, but it is still burning shareholder money.
What this measures
What is left after every cost, including tax and interest. The bottom line of the income statement.
What good looks like. Profit growing at least as fast as revenue, which means the business is keeping more of each sale as it gets bigger.
If it rises or falls. Profit can move for reasons revenue cannot explain - a one-off charge, a tax change, a write-down - so a single sharp year is worth checking against the margin chart before reading it as a trend.
What does “Growth” actually mean?
Growth here is what the company has actually reported to the SEC - not a forecast. We look at the last year, the three-year pace, whether growth is speeding up or slowing down, and whether it's been consistent rather than one lucky year. Hatched bars are fourth quarters we derived from annual filings (companies file a full-year 10-K rather than a Q4 report).
Profitability is thin or negative. The growth isn't turning into money yet.
-kept after direct costs
-kept after running costs
-36.1%profit on shareholders' money
-against a 10% cost of capital
-operating cash ÷ net income
Earnings quality
Does NAUT's operating cash flow keep up with its profit?
Year
Cash from operations
Net income
2,020
-14.0M
-15.6M
2,021
-39.2M
-50.3M
2,022
-45.8M
-57.9M
2,023
-51.7M
-63.7M
2,024
-59.1M
-70.8M
2,025
-50.7M
-59.0M
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→The company generated -$51M of operating cash in 2025. With no profit to compare against, cash generation is the number that matters here.
What this measures
Reported profit against the cash the business actually collected from operating. Profit is an accounting judgement; cash is not.
What good looks like. Cash at or above profit, year after year. Depreciation and other non-cash charges usually push cash above profit, so roughly 100% or more is healthy.
If it rises or falls. Cash falling behind profit for more than a year is the classic early warning: the sales are booked but the money has not arrived, and it shows up in receivables and inventory. For a lender the comparison behaves differently, because a growing loan book consumes cash.
Returns on capital
What return on equity and on capital does NAUT earn?
Year
ROE
ROA
ROCE
2,022
-0.1707
-0.1655
-
2,023
-0.2195
-0.2084
-
2,024
-0.2986
-0.2916
-
2,025
-0.3227
-0.3087
-
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year · each quarterly point is the trailing twelve months to that quarter end, so the last one is the current figure
→NAUT earns -36% on shareholders' capital. Return on capital employed isn't meaningful for this business model, so ROE carries the picture alone.
What this measures
Two returns side by side: on shareholders' capital (ROE), and on all the capital in the business including debt (ROCE).
What good looks like. Both comfortably above roughly 10%, and close together. A wide gap means borrowing, not operations, is doing the work.
If it rises or falls. A high ROE built on debt looks like quality until the debt has to be refinanced. ROCE is the harder number to flatter, which is why both are shown.
What does “Quality” actually mean?
Quality asks whether the growth makes real money. Margins show how much of each sale survives costs; return on equity shows what shareholders earn on their capital; and the profit-to-cash comparison catches companies whose accounting profits never turn into actual cash.
TTM operating cash flow -$50M on a net loss of $57M
IV
Financial health
●●●●●●4/6
Financially sound overall, with one or two things worth watching.
0.00xborrowed vs owned
10.1xnear-term bills coverage
-earnings ÷ interest bill
$84Mcash plus short-term investments
Debt & cash
How much debt does NAUT carry, and do its profits cover the interest?
Year
Total debt
Cash & investments
2,019
0
595,000
2,020
0
76.7M
2,021
0
345.7M
2,022
0
184.5M
2,023
0
173.4M
2,024
0
129.9M
2,025
0
103.4M
2,026
0
84.0M
◌ each quarterly point is the balance sheet at that quarter end
→The company holds $84M in cash against $0.00 of debt - a net-cash balance sheet, which means a bad year is an inconvenience rather than a threat.
What this measures
Total borrowings against cash on hand, with debt as a multiple of shareholders' equity, and how many times profit covers the interest bill.
What good looks like. Interest covered comfortably - roughly eight times or more - and debt that is not a large multiple of equity.
If it rises or falls. Debt is only a problem when it has to be repaid or refinanced in a bad year, so cover matters more than the amount. Rising debt with rising cover is a business borrowing to grow; rising debt with falling cover is the combination that ends badly.
Near-term liquidity
Do NAUT's current assets cover the bills due within a year?
Period
Current ratio
2020
25.7319
2021
60.0864
2022
27.5672
2023
19.3858
2024
17.4038
2025
13.3253
◌ 2026 = the latest balance sheet (2026-06-30), not a fiscal year-end · each quarterly point is the balance sheet at that quarter end
→Near-term liquidity is comfortable: 10.1x of current assets for every dollar due within the year. That is thinner than in 2020.
What this measures
Current assets over current liabilities: what the company can turn into cash within a year against what it owes within a year.
What good looks like. Comfortably above 1.0, and not falling year after year. Below 1.0 means near-term bills exceed near-term resources, which is normal for some business models and a warning in others.
If it rises or falls. Inventory and receivables build it up; short-term borrowing and payables pull it down. A retailer that turns stock over quickly can run lower than a manufacturer and be perfectly sound.
Shareholders' equity
Is NAUT's shareholder equity (book value) growing?
Period
Equity ($)
2019
-14.5M
2020
-29.7M
2021
363.6M
2022
314.9M
2023
265.4M
2024
208.7M
2025
157.0M
2026
131.1M
→The company's own capital shrank from $265M in 2023 to $131M (-51%). Buybacks or losses are drawing the buffer down - the distinction matters.
What this measures
What would be left for shareholders if every asset were sold at its book value and every debt repaid. Book value, in other words.
What good looks like. Equity growing as retained profits build up, unless the company is deliberately returning more than it earns.
If it rises or falls. Equity falls for two very different reasons: buybacks, which return money to you, and losses, which do not. The distinction is the whole story, and negative equity means liabilities now exceed assets, which makes debt-to-equity and return on equity meaningless rather than alarming.
What does “Health” actually mean?
Health asks one question: can the business survive a bad year? We check whether near-term bills are covered, whether debt is modest and shrinking, whether earnings comfortably pay the interest, and - for loss-makers - how many years of cash are left at the current burn rate.
NAUT returns nothing to shareholders yet, and the share count keeps rising. Every dollar stays in the business.
-bought back, TTM, over market value
-at the current rate
-dividends plus buybacks
$5Mlast 12m, dilutes the buybacks
+335.1%since 2020 (split-adjusted)
Share count change (split-adjusted)
Is NAUT's share count rising or falling?
Year
Share-count change
2,021
1.9036
2,022
0.4751
2,023
0.0026
2,024
0.0041
2,025
0.0066
→The share count grew 0.7% in 2025, averaging 0.4% a year over three years. Your slice of the company shrinks by that much each year unless earnings grow faster.
What this measures
The yearly change in the number of shares in issue, adjusted for splits so the years compare. A bar below zero is a falling share count, usually from buybacks; above zero, new shares were issued.
What good looks like. A flat or falling share count. Falling means each share you hold owns a little more of the business every year.
If it rises or falls. A rising count divides the same business among more owners, so your slice shrinks unless profits grow faster. This is the most direct chart on the page: it is your ownership, measured.
Why compare buybacks with stock compensation?
A company can trumpet billions in buybacks while quietly issuing nearly as much stock to employees. What matters to you is the net effect: is the share count actually falling? If not, the 'return' is mostly recycling.
→NAUT is in a clear uptrend: the price is above the cloud where recent trading settled, and that cloud is still rising underneath it. The last two weeks and the month-ago comparison both point up, so the shorter readings back the trend.
How the trend above is worked out
The trend read is the daily Ichimoku picture, the same indicator drawn on the chart above. Five names, and what each one is: the TENKAN is the midpoint of the last 9 sessions' high and low, the fast line; the KIJUN is the same over 26 sessions, the slow one; the two SENKOU spans are midpoints drawn 26 sessions into the FUTURE, and the band between them is the KUMO cloud - because it is drawn forward, the support for the coming weeks is already fixed and a change of its direction can be seen coming; the CHIKOU is today's close compared with the close 26 sessions back. A trend confirms itself in that order and the checks follow it: price clears the cloud, holds above both lines, the Tenkan crosses above the Kijun, the cloud ahead turns up, and the Chikou stands higher than the price a month ago. Six of six therefore means all of that at once; a price sitting inside the cloud, or below its own lines, cannot get there. The last check is the one Ichimoku cannot answer - whether the S&P 500 did better over 12 months (252 sessions), measured on the SPY ETF with dividends included, on the same adjusted basis as the stock's own price. Our figures are the last close we hold, refreshed every trading night; the chart is live. None of this says anything about the business, and it is not advice.
Are NAUT's insiders buying or selling shares with their own money?
Month
Buys ($)
Sells ($)
2024-03
140,532
0
2024-04
0
0
2024-05
0
0
2024-06
0
0
2024-07
0
0
2024-08
0
0
2024-09
0
234,613
2024-10
0
0
2024-11
0
0
2024-12
0
0
2025-01
0
0
2025-02
0
0
2025-03
76,918
0
2025-04
0
0
2025-05
21,374
0
2025-06
0
0
2025-07
0
0
2025-08
0
0
2025-09
148,433
0
2025-10
0
0
2025-11
5,960
0
2025-12
0
0
2026-01
0
0
2026-02
0
0
2026-03
65,238
0
2026-04
0
0
2026-05
0
0
2026-06
0
11.8M
2026-07
0
0
2026-08
0
0
2026-09
0
0
2026-10
0
0
→Since March 2024, insiders bought $458,454 and sold $12M on the open market, a net sale of $12M. A further 2 transactions were grants, option exercises or tax withholding, which say nothing either way.
What this measures
Open-market buys and sells by the company's own officers and directors, from their Form 4 filings. Grants, option exercises and shares withheld for tax are excluded, because they are compensation rather than decisions.
What good looks like. Buying with their own money, which is the one insider action that is hard to explain away.
If it rises or falls. Selling is weak evidence: insiders sell to diversify, to buy houses, and on pre-scheduled plans set months ahead. Buying is stronger evidence, because there is only one reason to do it. The absence of any buying over a long stretch is itself worth noticing.
The record
Who did what, exactly?
Date
Insider
Role
Type
Shares
Price
Value
2026-06-02
Ah Equity Partners Bio II, L.L.C.
10% owner
SELL
4,615,974
$2.35
$10.85M
2026-06-02
Ah Equity Partners Bio II, L.L.C.
10% owner
SELL
384,026
$2.35
$902,461
2026-03-04
Sujal M Patel
CEO, President, and Secretary
BUY
25,000
$2.61
$65,238
2025-11-06
Kentaro Suzuki
Chief Marketing Officer
BUY
4,000
$1.49
$5,960
2025-09-08
Sujal M Patel
CEO, President, and Secretary
BUY
83,500
$0.68
$57,031
2025-09-05
Sujal M Patel
CEO, President, and Secretary
BUY
116,500
$0.67
$78,544
2025-09-04
Matthew B. Murphy
General Counsel
BUY
20,000
$0.64
$12,858
2025-05-29
Anna Mowry
CFO and Treasurer
BUY
15,000
$0.77
$11,489
2025-05-12
Parag Mallick
Chief Scientist
BUY
1,500
$0.73
$1,098
2025-05-08
Parag Mallick
Chief Scientist
BUY
12,000
$0.73
$8,788
2025-03-20
Sujal M Patel
CEO, President, and Secretary
BUY
23,933
$1.00
$23,890
2025-03-19
Sujal M Patel
CEO, President, and Secretary
BUY
53,300
$0.99
$53,028
2024-09-23
Mary E. Godwin
Senior VP, Operations
exercise
47,031
$0.46
$21,634
2024-09-23
Mary E. Godwin
Senior VP, Operations
SELL
47,031
$2.87
$134,744
2024-09-17
Mary E. Godwin
Senior VP, Operations
exercise
35,000
$0.46
$16,100
2024-09-17
Mary E. Godwin
Senior VP, Operations
SELL
35,000
$2.85
$99,869
2024-03-11
Sujal M Patel
CEO, President, and Secretary
BUY
12,044
$2.84
$34,216
2024-03-08
Sujal M Patel
CEO, President, and Secretary
BUY
2,430
$2.99
$7,262
2024-03-07
Sujal M Patel
CEO, President, and Secretary
BUY
18,854
$2.89
$54,424
2024-03-06
Sujal M Patel
CEO, President, and Secretary
BUY
9,267
$2.70
$25,034
2024-03-05
Sujal M Patel
CEO, President, and Secretary
BUY
7,405
$2.65
$19,597
Why do the transaction types matter so much?
Most insider filings are not trades: stock grants, option exercises and tax withholding are how executives get paid, and gifts are estate planning. The signal lives in open-market transactions - a buy means an insider chose to spend their own cash on the stock. Sells are murkier: many are pre-scheduled 10b5-1 plans set months in advance. That's why the chart counts only open-market activity, and the table labels every row.
VIII
Ownership
informational
39.4%on Form 13F, 30 June 2026
39.9%officers, directors, founders
69.0%together
Top holders
Who owns Nautilus Biotechnology stock?
Fund managers filing Form 13F held 39.4% of the company's shares on 30 June 2026. The largest holder is Parag Mallick, with 16.1%. Insiders hold 39.9%.
#
Holder
Stake
Shares
Value
Change
1
Parag MallickChief Scientist · Form 4, 8 May 2025
16.10%
20.5M
$42M
-
2
Sujal M PatelCEO, President, and Secretary · Form 4, 4 March 2026
13.72%
17.5M
$36M
-
3
Ah Equity Partners Bio II, L.L.C.10% owner · Form 4, 2 June 2026
Source: SEC Form 13F filings for the quarter to 30 June 2026, Schedules 13D and 13G, and Form 4. Shares on today's basis, value at the latest price.
Where does this list come from?
Fund managers with more than $100 million in US stocks report their holdings every quarter on Form 13F, up to 45 days after the quarter ends, so the fund figures are as of the last quarter end. A fund family reports as one manager, and funds together can report more than 100%: shares lent to short sellers are bought again by other funds, and both report them. Anyone holding more than 5% of a class files a Schedule 13D or 13G, and officers and directors report what they hold on Form 4 after every trade, so those rows carry their own dates. Short positions are not reported anywhere. A stake is the holder's shares as a share of all the company's shares, with other share classes converted at their market value.